

Manuela Vaneckova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6599317/publications.pdf>

Version: 2024-02-01

91
papers

2,401
citations

186209

28
h-index

233338

45
g-index

91
all docs

91
docs citations

91
times ranked

2751
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinical and paraclinical correlates of employment status in multiple sclerosis. <i>Neurological Sciences</i> , 2022, 43, 1911-1920.	0.9	4
2	Pregnancy-induced brain magnetic resonance imaging changes in women with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 1446-1456.	1.7	7
3	Time course of lesion-induced atrophy in multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 4478-4487.	1.8	3
4	Periventricular gradient of T1 tissue alterations in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2022, 34, 103009.	1.4	9
5	Oxidative Stress Markers in Cerebrospinal Fluid of Newly Diagnosed Multiple Sclerosis Patients and Their Link to Iron Deposition and Atrophy. <i>Diagnostics</i> , 2022, 12, 1365.	1.3	2
6	Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 220-231.	1.4	55
7	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 52-60.	1.4	41
8	Interpretation of Brain Volume Increase in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 401-407.	1.0	6
9	Efficiency of ¹²³ I-ioflupane SPECT as the marker of basal ganglia damage in acute methanol poisoning: 6-year prospective study. <i>Clinical Toxicology</i> , 2021, 59, 235-245.	0.8	2
10	Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. <i>Diagnostics</i> , 2021, 11, 464.	1.3	9
11	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	15
12	White matter alteration and cerebellar atrophy are hallmarks of brain MRI in alpha-mannosidosis. <i>Molecular Genetics and Metabolism</i> , 2021, 132, 189-197.	0.5	8
13	Non-Penetrance for Ocular Phenotype in Two Individuals Carrying Heterozygous Loss-of-Function ZEB1 Alleles. <i>Genes</i> , 2021, 12, 677.	1.0	3
14	Detailed Phenotype of GLA Variants Identified by the Nationwide Neurological Screening of Stroke Patients in the Czech Republic. <i>Journal of Clinical Medicine</i> , 2021, 10, 3543.	1.0	3
15	Age-related magnetic susceptibility changes in deep grey matter and cerebral cortex of normal young and middle-aged adults depicted by whole brain analysis. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 3906-3919.	1.1	16
16	Validating atlas-based lesion disconnectomics in multiple sclerosis: A retrospective multi-centric study. <i>NeuroImage: Clinical</i> , 2021, 32, 102817.	1.4	4
17	Novel disease-causing variants and phenotypic features of X-linked megalocornea. <i>Acta Ophthalmologica</i> , 2021, , .	0.6	1
18	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2001-2013.	1.4	9

#	ARTICLE	IF	CITATIONS
19	Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis. <i>Diagnostics</i> , 2021, 11, 2230.	1.3	2
20	Pontocerebellar atrophy is the hallmark neuroradiological finding in late-onset Tay-Sachs disease. <i>Neurological Sciences</i> , 2021, , 1.	0.9	1
21	The impact of co-morbidities on a 6-year survival after methanol mass poisoning outbreak: possible role of metabolic formaldehyde. <i>Clinical Toxicology</i> , 2020, 58, 241-253.	0.8	12
22	Health-related quality of life determinants in survivors of a mass methanol poisoning outbreak: six-year prospective cohort study. <i>Clinical Toxicology</i> , 2020, 58, 870-880.	0.8	6
23	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. <i>Journal of Clinical Lipidology</i> , 2020, 14, 675-684.e2.	0.6	8
24	MRI-based brain volumetry and retinal optical coherence tomography as the biomarkers of outcome in acute methanol poisoning. <i>NeuroToxicology</i> , 2020, 80, 12-19.	1.4	6
25	Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102543.	0.9	13
26	Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642097522.	1.5	5
27	Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis. <i>BioMed Research International</i> , 2020, 2020, 1-6.	0.9	13
28	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	24
29	Multisystem mitochondrial diseases due to mutations in mtDNA-encoded subunits of complex I. <i>BMC Pediatrics</i> , 2020, 20, 41.	0.7	23
30	Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 820.	1.1	16
31	Reactive carbonyl compounds, carbonyl stress, and neuroinflammation in methyl alcohol intoxication. <i>Monatshefte für Chemie</i> , 2019, 150, 1723-1730.	0.9	3
32	Lifespan normative data on rates of brain volume changes. <i>Neurobiology of Aging</i> , 2019, 81, 30-37.	1.5	40
33	Markers of nucleic acids and proteins oxidative damage in acute methanol poisoning. <i>Monatshefte für Chemie</i> , 2019, 150, 477-487.	0.9	4
34	Brain volumetric correlates of dysarthria in multiple sclerosis. <i>Brain and Language</i> , 2019, 194, 58-64.	0.8	16
35	Methanol Poisoning as an Acute Toxicological Basal Ganglia Lesion Model: Evidence from Brain Volumetry and Cognition. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1486-1497.	1.4	12
36	Anterior hippocampus volume loss in narcolepsy with cataplexy. <i>Journal of Sleep Research</i> , 2019, 28, e12785.	1.7	12

#	ARTICLE	IF	CITATIONS
37	Clinical and genetic determinants of chronic visual pathway changes after methanol - induced optic neuropathy: four-year follow-up study. <i>Clinical Toxicology</i> , 2019, 57, 387-397.	0.8	20
38	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 541-553.	1.4	32
39	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2018, 388, 87-93.	0.3	7
40	Establishing pathological cut-offs for lateral ventricular volume expansion rates. <i>NeuroImage: Clinical</i> , 2018, 18, 494-501.	1.4	26
41	The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018, 28, 328-337.	1.0	4
42	Role of activation of lipid peroxidation in the mechanisms of acute methanol poisoning. <i>Clinical Toxicology</i> , 2018, 56, 893-903.	0.8	10
43	Cognitive clinico-radiological paradox in early stages of multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 81-91.	1.7	26
44	Progressive Chronic Retinal Axonal Loss Following Acute Methanol-induced Optic Neuropathy: Four-Year Prospective Cohort Study. <i>American Journal of Ophthalmology</i> , 2018, 191, 100-115.	1.7	30
45	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. <i>NeuroImage: Clinical</i> , 2018, 17, 444-451.	1.4	58
46	Characteristics of motor speech phenotypes in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 62-69.	0.9	58
47	Reply. <i>American Journal of Ophthalmology</i> , 2018, 195, 247-248.	1.7	0
48	Neuroinflammation markers and methyl alcohol induced toxic brain damage. <i>Toxicology Letters</i> , 2018, 298, 60-69.	0.4	13
49	Gait and Balance Impairment after Acute Methanol Poisoning. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 176-182.	1.2	15
50	Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 242-252.	1.4	39
51	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 51-61.	1.4	39
52	Leukotriene-mediated neuroinflammation, toxic brain damage, and neurodegeneration in acute methanol poisoning. <i>Clinical Toxicology</i> , 2017, 55, 249-259.	0.8	24
53	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study. <i>Journal of Neuroimaging</i> , 2017, 27, 620-629.	1.0	20
54	Is Chelation Therapy Efficient for the Treatment of Intravenous Metallic Mercury Intoxication?. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 628-633.	1.2	7

#	ARTICLE	IF	CITATIONS
55	Serum lipid profile changes predict neurodegeneration in interferon- β 1a-treated multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2017, 58, 403-411.	2.0	43
56	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2017, 15, 769-779.	1.4	48
57	Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1336-1345.	1.4	93
58	Acute Methanol Poisoning: Prevalence and Predisposing Factors of Haemorrhagic and Non-Haemorrhagic Brain Lesions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 228-238.	1.2	42
59	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 777-793.	1.4	126
60	Reliable measurements of brain atrophy in individual patients with multiple sclerosis. <i>Brain and Behavior</i> , 2016, 6, e00518.	1.0	58
61	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1709-1718.	1.4	69
62	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. <i>Multiple Sclerosis Journal</i> , 2016, 22, 770-781.	1.4	37
63	Successful Use of Hydroxocobalamin and Sodium Thiosulfate in Acute Cyanide Poisoning: A Case Report with Follow-up. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 209-212.	1.2	23
64	Rare Alleles within the <i>CYP2E1</i> (<i>MEOS</i> System) Could be Associated with Better Short-Term Health Outcome after Acute Methanol Poisoning. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 168-172.	1.2	21
65	Long-term visual damage after acute methanol poisonings: Longitudinal cross-sectional study in 50 patients. <i>Clinical Toxicology</i> , 2015, 53, 884-892.	0.8	78
66	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2015, 56, 2010-2018.	2.0	45
67	Hippocampal but not amygdalar volume loss in narcolepsy with cataplexy. <i>Neuroendocrinology Letters</i> , 2015, 36, 682-8.	0.2	2
68	Imaging findings after methanol intoxication (cohort of 46 patients). <i>Neuroendocrinology Letters</i> , 2015, 36, 737-44.	0.2	23
69	MRI correlates of disability progression in patients with CIS over 48 months. <i>NeuroImage: Clinical</i> , 2014, 6, 312-319.	1.4	39
70	Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. <i>Journal of the Neurological Sciences</i> , 2014, 347, 229-234.	0.3	8
71	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. <i>Journal of Neuroimmunology</i> , 2014, 273, 58-64.	1.1	21
72	Czech mass methanol outbreak 2012: Epidemiology, challenges and clinical features. <i>Clinical Toxicology</i> , 2014, 52, 1013-1024.	0.8	108

#	ARTICLE	IF	CITATIONS
73	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 424-433.	1.2	14
74	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 859-864.	0.9	35
75	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. <i>Journal of Neurology</i> , 2014, 261, 1735-1744.	1.8	45
76	Development of gray matter atrophy in relapsingâ€“remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, S42-S48.	0.6	12
77	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , 2013, 263, 121-127.	1.1	14
78	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. <i>Radiology</i> , 2013, 268, 831-841.	3.6	145
79	Lipid profiles are associated with lesion formation over 24â€“months in interferon-Î² treated patients following the first demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1186-1191.	0.9	114
80	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-8.	0.4	9
81	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. <i>PLoS ONE</i> , 2013, 8, e53996.	1.1	68
82	Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study. <i>PLoS ONE</i> , 2012, 7, e50101.	1.1	73
83	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. <i>Journal of Neuroimmunology</i> , 2011, 236, 76-80.	1.1	12
84	Post-mortem magnetic resonance imaging and its irreplaceable role in determining CNS malformation (hydranencephaly) â€“ Case report. <i>Brain and Development</i> , 2010, 32, 417-420.	0.6	10
85	Benefits of examination by post mortem performed magnetic resonance imaging of foetus: haemorrhage in germinal matrix. <i>Neuroendocrinology Letters</i> , 2010, 31, 40-2.	0.2	1
86	Is it always possible to determine a diagnosis? Prenatal ultrasonography, post mortem magnetic resonance, autopsy. <i>Neuroendocrinology Letters</i> , 2010, 31, 178-80.	0.2	1
87	Patientsâ€™ Stratification and Correlation of Brain Magnetic Resonance Imaging Parameters with Disability Progression in Multiple Sclerosis. <i>European Neurology</i> , 2009, 61, 278-284.	0.6	10
88	Gray matter atrophy and disability progression in patients with early relapsingâ€“remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2009, 282, 112-119.	0.3	84
89	MRI volumetry of the amygdala: an anatomic background. <i>FASEB Journal</i> , 2008, 22, 975.1.	0.2	0
90	Detection of Cortical Lesions is Dependent on Choice of Slice Thickness in Patients with Multiple Sclerosis. <i>International Review of Neurobiology</i> , 2007, 79, 475-489.	0.9	25

#	ARTICLE	IF	CITATIONS
91	Macroprolactinomas: retrospective follow up study in the MR imaging and correlation with clinical symptomatology. <i>Neuroendocrinology Letters</i> , 2007, 28, 841-5.	0.2	4